$ARAI

Arrive AI (ARAI) has partnered with DXC Technology to integrate its Arrive Point delivery infrastructure into large-scale manufacturing environments. DXC's expertise will help connect Arrive AI's technology with existing systems, aiming to improve material movement efficiency. The partnership was first disclosed in Arrive AI's Q2 2026 earnings release.

Arrive AI (ARAI) highlighted an independent whitepaper naming its Arrive Point as a model for solving medical drone delivery's last-inch problem. The paper, by AeroX, estimates the global medical drone delivery market at $294M, growing to $2.5B by 2034. Arrive AI's technology enables secure, asynchronous exchange of goods for drones, robots, and human couriers.

Arrive AI (NASDAQ:ARAI) amended its financing agreement with Streeterville Capital, reducing the floor price from $0.25 to $0.10 per share and removing a $962,500 monthly repayment obligation. The company issued a new $108,000 unsecured promissory note. Management views this as a positive development, enhancing financial flexibility and allowing focus on execution and long-term value creation.

Arrive AI (ARAI) announced a strategic workforce reduction of 20%, expected to generate $1.5M in annualized savings. The company forfeited 450,000 unvested shares. Management cites AI advancements and a clearer mission for the changes, aiming to streamline operations and focus resources on high-priority areas.

Arrive AI Inc. (ARAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement Pre-Paid Purchase No. 5 and Reduction of Floor Price Trigger As previously disclosed, on August 6, 2026, the volume-weighted average price (“VWAP”) of the common stock of Arrive AI Inc. (the “Company”) fell below the floor pri

Arrive AI (ARAI) held its Q2 2026 earnings call. Management reported revenue of $14.7 million, a net loss of $14.1 million, and non-GAAP net loss of $4.3 million. Cash and liquid investments were $5.1 million at June 30, with about $1.1 million monthly burn. The company outlined AP3 Plus shipments, a 2027 ramp, and financing capacity via an S-3 and $15 million ATM.

Arrive AI Inc. (ARAI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 2.04. Triggering Events That Accelerate or Increase a Direct Financial Obligation On August 6, 2026, the volume weighted average price (“VWAP”) of the common stock, par value $0.0002 per share (“Common Stock”), of Arrive AI Inc. (the “Company”) fell below $0.25 per share (th

Arrive AI (NASDAQ:ARAI) said it signed a non-binding letter of intent with LifeSpan Pharmacy to explore a phased autonomous drone pharmacy delivery program in the Indianapolis area. The first phase would include a live demonstration flight delivering pharmaceuticals and validating the corridor, with possible pilot and expansion steps later, subject to agreement.

Arrive AI Inc. (ARAI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 27, 2026, Todd Pepmeier, Chief Financial Officer of Arrive AI Inc. (the “ Company ”), notified the Company of his

Arrive AI (NASDAQ:ARAI) said it will report Q2 2026 results on Aug. 13, 2026 before market open, followed by an 8:30 a.m. ET webcast and conference call to review results and recent developments. The company may use AI-assisted voice for parts of prepared remarks, with disclosure. A replay will be available afterward.